Skip to content
Clinical Trials – home

Institut Jules Bordet

Research siteFast reply

Belgium Mijlenmeersstraat 90, 1070 Anderlecht, Belgium

  • 92 trials recruiting
  • Breast cancer · Non-small cell lung cancer · Breast cancer metastatic
  • Adults and children

About Specializations

Institut Jules Bordet in Anderlecht, Belgium specialises in clinical trials of conditions such as Breast cancer, Non-small cell lung cancer, Breast cancer metastatic, Colorectal cancer, and other specialisations. This site conducts important research.

Main research areas of the site

Oncology

The medical center is at the forefront of oncology research, focusing on innovative treatments for various types of cancer. The center's research includes exploring novel therapeutic combinations and targeted therapies to improve patient outcomes.

  • Advanced Solid Tumors
  • Breast Cancer
  • Colorectal Cancer
  • Renal Cell Carcinoma
  • Prostate Cancer

By integrating cutting-edge research with clinical practice, the center aims to enhance the efficacy and safety of cancer treatments, offering hope to patients with challenging diagnoses.

Hematology

Specializing in hematology, the center conducts pioneering research on blood disorders, focusing on innovative therapies for conditions such as lymphoma and leukemia. The research aims to improve survival rates and quality of life for patients.

  • Follicular Lymphoma
  • Marginal Zone Lymphoma
  • Acute Lymphoblastic Leukemia
  • Multiple Myeloma

The center's commitment to advancing hematological research is evident in its development of novel therapeutic strategies and its focus on personalized medicine.

Immunotherapy

At the cutting edge of immunotherapy, the center explores the potential of immune-based treatments to combat various cancers. This research is pivotal in developing therapies that harness the body's immune system to target and destroy cancer cells.

  • Gene-Modified T Cells
  • Checkpoint Inhibitors
  • Bispecific Antibodies

Through its innovative research, the center is contributing to the evolution of cancer treatment, offering new hope for patients with previously untreatable conditions.

Endocrinology

The center's research in endocrinology focuses on hormone-related cancers, particularly breast and prostate cancer. By investigating the role of hormones in cancer progression, the center aims to develop targeted therapies that improve patient outcomes.

  • Hormone Receptor-Positive Breast Cancer
  • Metastatic Hormone-Sensitive Prostate Cancer

Through its research, the center is advancing the understanding of hormone-driven cancers and developing therapies that offer more effective treatment options.

Gastroenterology

In the field of gastroenterology, the center is dedicated to researching advanced treatments for gastrointestinal cancers. This includes exploring new drug combinations and targeted therapies to improve survival rates and quality of life for patients.

  • Colorectal Cancer
  • Gastric and Gastroesophageal Junction Adenocarcinoma

The center's research efforts are focused on developing innovative treatment strategies that address the unique challenges of gastrointestinal cancers.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location
Mijlenmeersstraat 901070 AnderlechtBelgium
Recruiting now
92 trials
Conditions studied
126

More sites in AnderlechtBelgium

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

218 clinical trials

Study of sotorasib, panitumumab and a drug combination for patients with metastatic colorectal cancer with KRAS p.G12C mutation.

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years
  • Substances:Bevacizumab
  • Sponsor:Amgen Inc.

A study comparing XL092 versus everolimus in patients with previously treated advanced or metastatic neuroendocrine tumors

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Everolimus
  • Sponsor:Exelixis Inc.

A Study of Ivonescimab Combined with Fluorouracil, Folinic Acid, and Oxaliplatin Compared to Bevacizumab for Patients with Metastatic Colorectal Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Summit Therapeutics Inc.

Study of personalized treatment using drug combination therapy for young women with early stage hormone receptor-positive breast cancer based on gene expression testing

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years
  • Substances:Anastrozole
  • Sponsor:Unicancer

Study of Ifinatamab Deruxtecan and Chemotherapy for Patients with Advanced or Metastatic Esophageal Squamous Cell Carcinoma

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Docetaxel
  • Sponsor:Daiichi Sankyo Inc.

Study of Tucatinib, Trastuzumab, and mFOLFOX6 for Patients with HER2+ Metastatic Colorectal Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Seagen Inc.

Study on the Long-term Safety and Efficacy of Pembrolizumab and Lenvatinib for Patients with Advanced Tumors

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Favezelimab
  • Sponsor:Merck Sharp & Dohme LLC

Study of Rinatabart Sesutecan with glatiramer acetate in patients with advanced gastrointestinal cancers

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Glatiramer Acetate
  • Sponsor:Genmab A/S

Neoplasm

Recruiting

Phase 1/2 Study of ter-2013-01, imlunestrant, and fulvestrant in patients with solid tumors with AKT/PI3K/PTEN pathway alterations

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Fulvestrant

Comparing Daraxonrasib Alone or Combined with Gemcitabine and Paclitaxel Albumin‑Bound vs Standard Chemotherapy in Patients with Metastatic Pancreatic Adenocarcinoma

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Gemcitabine
  • Sponsor:Revolution Medicines Inc.

Colorectal cancer+2

Recruiting

Study of RMC-6291 with ivonescimab drug combination in patients with advanced RAS‑mutated solid tumors

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Revolution Medicines Inc.

Study of telisotuzumab adizutecan plus drug combination in adults with refractory metastatic colorectal cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG
Is this your site?

Join our network of research sites

Get verified: confirm your contact details and recruitment status with us, appear first on the pages of your trials and receive patient requests directly.

See the offer for sites
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.